Use of WX-UK1 and its prodrug WX-671 for the treatment of non-cancerous medical conditions

摘要

The present invention relates to a method of treating an animal with a non-cancerous medical condition ameliorated by treatment with a trypsin inhibitor, the method comprising obtaining a biological sample from the animal; Testing the sample to obtain a trypsin concentration, wherein if the trypsin concentration exceeds the upper limit of steady state, the animal is a pharmaceutically acceptable carrier and the compound N-α- (2,4,6-triisopropylphenyl. Sulfonyl) -3-hydroxyamidino-phenylalanine-4-ethoxycarbonylpiperazide, stereoisomers thereof, racemic mixtures, metabolites, pharmaceutically acceptable salts, crystals, or any combination It is treated for a suitable period of time by administering a therapeutically effective amount of the pharmaceutical composition to the animal. In one embodiment, the non-cancerous medical condition is an inflammatory digestive disease selected from the group consisting of pancreatitis, gastritis, irritable bowel syndrome, and inflammatory bowel disease. In one embodiment, the pharmaceutical composition is in an orally administrable form.